Efficacy and safety of sintilimab plus XELOX as neoadjuvant therapy in patients with locally advanced gastric cancer: A single-arm open-label phase II trial
第一作者机构：[1]Fourth Hosp Hebei Med Univ, Dept Surg 3, Shijiazhuang, Peoples R China
通讯作者：
通讯机构：[1]Fourth Hosp Hebei Med Univ, Dept Surg 3, Shijiazhuang, Peoples R China
推荐引用方式(GB/T 7714)：
Guo Honghai,Ding Ping'an,Yang Peigang,et al.Efficacy and safety of sintilimab plus XELOX as neoadjuvant therapy in patients with locally advanced gastric cancer: A single-arm open-label phase II trial[J].JOURNAL OF CLINICAL ONCOLOGY.2022,40(16):E16091-E16091.doi:10.1200/JCO.2022.40.16_suppl.e16091.
APA：
Guo, Honghai,Ding, Ping'an,Yang, Peigang,Tian, Yuan,Liu, Yang...&Zhao, Qun.(2022).Efficacy and safety of sintilimab plus XELOX as neoadjuvant therapy in patients with locally advanced gastric cancer: A single-arm open-label phase II trial.JOURNAL OF CLINICAL ONCOLOGY,40,(16)
MLA：
Guo, Honghai,et al."Efficacy and safety of sintilimab plus XELOX as neoadjuvant therapy in patients with locally advanced gastric cancer: A single-arm open-label phase II trial".JOURNAL OF CLINICAL ONCOLOGY 40..16(2022):E16091-E16091
医学